1 |
Luo H, Song G, Wang D, Li M, Dai N. Combining PD-1 or PD-L1 inhibitors with chemotherapy is a good strategy for the treatment of extensive small cell lung cancer: A retrospective analysis of clinical studies. Front Immunol 2022;13:1059557. [PMID: 36544769 DOI: 10.3389/fimmu.2022.1059557] [Reference Citation Analysis]
|
2 |
Niu X, Chen L, Li Y, Hu Z, He F. Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC. Semin Cancer Biol 2022;86:273-85. [PMID: 35288298 DOI: 10.1016/j.semcancer.2022.03.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 44.0] [Reference Citation Analysis]
|
3 |
Zhang H, Kong W, Liang W. NUT Midline Carcinoma: A Rare Solid Tumour Characterized by Chromosome Rearrangement. Evid Based Complement Alternat Med 2022;2022:3369895. [PMID: 35832518 DOI: 10.1155/2022/3369895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
4 |
Meijer JJ, Leonetti A, Airò G, Tiseo M, Rolfo C, Giovannetti E, Vahabi M. Small cell lung cancer: novel treatments beyond immunotherapy. Semin Cancer Biol 2022:S1044-579X(22)00115-8. [PMID: 35568295 DOI: 10.1016/j.semcancer.2022.05.004] [Reference Citation Analysis]
|
5 |
Yin X, Li Y, Wang H, Jia T, Wang E, Luo Y, Wei Y, Qin Z, Ma X. Small cell lung cancer transformation: From pathogenesis to treatment. Semin Cancer Biol 2022:S1044-579X(22)00062-1. [PMID: 35276343 DOI: 10.1016/j.semcancer.2022.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
|